Corvus Pharmaceuticals (CRVS) Expected to Release Quarterly Earnings on Thursday

Corvus Pharmaceuticals (NASDAQ:CRVS) is expected to issue its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect Corvus Pharmaceuticals to announce earnings of ($0.17) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its earnings results on Thursday, May 7th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01). On average, analysts expect Corvus Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Corvus Pharmaceuticals Stock Up 4.1%

Shares of NASDAQ CRVS opened at $13.92 on Wednesday. The firm’s 50-day simple moving average is $13.33 and its 200 day simple moving average is $15.26. The company has a market cap of $1.17 billion, a price-to-earnings ratio of -26.77 and a beta of 0.87. Corvus Pharmaceuticals has a 12-month low of $4.05 and a 12-month high of $26.95.

Insider Buying and Selling at Corvus Pharmaceuticals

In other Corvus Pharmaceuticals news, Director David Scott Moore acquired 21,700 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were acquired at an average cost of $11.53 per share, for a total transaction of $250,201.00. Following the completion of the acquisition, the director directly owned 21,700 shares of the company’s stock, valued at approximately $250,201. This represents a ? increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 19.70% of the stock is currently owned by company insiders.

Institutional Trading of Corvus Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in CRVS. Price T Rowe Associates Inc. MD boosted its position in shares of Corvus Pharmaceuticals by 5.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 34,105 shares of the company’s stock worth $263,000 after purchasing an additional 1,696 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Corvus Pharmaceuticals by 6.0% in the third quarter. JPMorgan Chase & Co. now owns 32,232 shares of the company’s stock valued at $238,000 after buying an additional 1,812 shares during the period. Deutsche Bank AG boosted its holdings in Corvus Pharmaceuticals by 4.5% during the fourth quarter. Deutsche Bank AG now owns 56,039 shares of the company’s stock worth $432,000 after buying an additional 2,400 shares during the last quarter. Quarry LP acquired a new position in shares of Corvus Pharmaceuticals during the 3rd quarter worth about $27,000. Finally, Ancora Advisors LLC increased its stake in shares of Corvus Pharmaceuticals by 9.7% in the 3rd quarter. Ancora Advisors LLC now owns 47,290 shares of the company’s stock valued at $349,000 after acquiring an additional 4,183 shares during the last quarter. Institutional investors own 46.64% of the company’s stock.

Wall Street Analysts Forecast Growth

CRVS has been the subject of several research reports. Weiss Ratings upgraded shares of Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 28th. LADENBURG THALM/SH SH raised shares of Corvus Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, July 30th. The Goldman Sachs Group assumed coverage on shares of Corvus Pharmaceuticals in a research note on Friday, April 17th. They set a “buy” rating and a $40.00 price target on the stock. Finally, Wall Street Zen cut shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $33.33.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.